Pheniramine

Pheniramine

Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy category	AU: A
intravenous); topical (ophthalmic/nasal solution)
ATC code	D04AA16 (WHO) R06AB05 (WHO)
Pharmacokinetic data
Metabolism	Hepatic hydroxylation, demethylation and glucuronidation
Elimination half-life	16 - 19 hrs (oral), 8 - 7 hrs (i.v.)[1]
Excretion	Renal
Identifiers
IUPAC name N,N-Dimethyl-3-phenyl-3-pyridin-2-yl-propan-1-amine
JSmol)	Interactive image
SMILES n1ccccc1C(c2ccccc2)CCN(C)C
InChI InChI=1S/C16H20N2/c1-18(2)13-11-15(14-8-4-3-5-9-14)16-10-6-7-12-17-16/h3-10,12,15H,11,13H2,1-2H3 Y Key:IJHNSHDBIRRJRN-UHFFFAOYSA-N Y
(verify)

Pheniramine (trade name Avil among others) is an

It was patented in 1948.[2] Pheniramine is generally sold in combination with other medications, rather than as a stand-alone drug, although some formulations are available containing pheniramine by itself.

Side effects

Pheniramine may cause drowsiness or Tachycardia, and over-dosage may lead to sleep disorders.^{[citation needed]}

Overdose may lead to

People combining with cortisol in the long term should avoid pheniramine as it may decrease levels of adrenaline (epinephrine) which may lead to loss of consciousness.^{[citation needed]}

Pheniramine is a

Halogenation of pheniramine increases its potency 20-fold. Halogenated derivatives of pheniramine include chlorphenamine, brompheniramine, dexchlorpheniramine, dexbrompheniramine, and zimelidine. Two other halogenated derivatives, fluorpheniramine and iodopheniramine, are currently in use for research on combination therapies for malaria and some cancers. ^{[citation needed]}

Other analogs include diphenhydramine, and doxylamine.

Stereoisomerism

Pheniramine contains a stereocenter and can exists as either of two

Enantiomers of pheniramine
(R)-Pheniramine CAS number: 56141-72-1	(S)-Pheniramine CAS number: 23201-92-5

See also

• Development and discovery of SSRI drugs

References